Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Hybrid Assistive Limb Application in Multiple Sclerosis Patients

NCT07326852 · Ege University · Updated 7 July 2026

What is being tested
Hybrid Assistive Limb (HAL)
For
Multiple Sclerosis
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 18 years to 50 years. About 13 people. The full rules are on the registry page.
Where
Turkey (Türkiye)
When
Starts or started 8 Oct 2025, ends 9 Feb 2026. Registered 8 Jan 2026.
Results
None posted yet.

In the researchers' words

The Hybrid Assistive Limb (HAL) exoskeleton detects bioelectrical signals from the muscles, responds to the intention of voluntary movement, and provides biological feedback. In this study, the effects of HAL application on walking performance and balance in patients with multiple sclerosis will be examined in a single-center, controlled design. Participants will undergo walking rehabilitation with HAL for 1 hour per day, 5 days a week, for a total of 2 months. Walking and balance performance will be assessed before and after the intervention using the 10-Minute Walk Test (10MWT) to measure maximum walking speed, the 6-Minute Walk Test (6MWT) to evaluate walking endurance and cardiorespiratory performance, and the Timed Up and Go Test (TUG) to assess functional mobility and dynamic balance. Additionally, walking parameters and static balance will be measured using Tecnobody systems. Appropriate statistical tests will be applied, and a significance level of p\<0.05 will be considered.
ClinicalTrials.gov, NCT07326852

Sites

  • Ege UniversityIzmir, Karşıyaka, Turkey (Türkiye)